coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Dartford Central PCN, Dartford · Health Inequalities Profile

    PCN U10200 · NHS Kent and Medway Integrated Care Board · 3 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    41,974

    Registered population

    61.5% aged 18–64

    13.8%

    Aged 65+

    ICB 19.9% · England 17.9%

    27.3%

    Ethnic minority (non-White)

    10.4% Asian · England 9.6%

    10.9%

    In IMD quintile 1

    ICB 17.1% · England 21.0%

    ~4,065

    Core20 residents (est.)

    Resident basis; registered basis ~4,760 · see page 3

    7,170

    Hypertension register

    +20.19% in 3 yrs · England +5.60%

    371

    SMI register

    33.5% of Dartford's

    541

    COPD register

    Reviews -17.02% in 3 yrs

    Forecast to 2030

    11,394

    Hypertension patients, 2030

    +4,224 on today

    89.8%

    QRISK ≥20% on statins, 2030

    +10.05pp over 3 yrs

    3.6%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    60.3%
    Hypertension BP control lags national benchmark.

    Hypertension treated to target is 60.3% (England 70.3%, down 8.1%), and under-80s BP control is 56.5% (England 67.8%, down 9.4%).

    79.7%
    Pre-school booster and MMR2 below 95% target.

    Age-5 4-in-1 coverage is 79.7% (15.3 pp below the 95.0% target) and MMR2 is 81.2%, 10.8 pp below age-5 MMR1 at 92.0%.

    +18.8%
    Rapid growth in lipid-lowering therapy uptake.

    QRISK ≥ 20% lipid-lowering therapy rose +18.8% (England +6.2%) to 63.7% (England 63.6%), while CKD lipid therapy reaches 77.3% (England 70.3%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Younger age structure and 27.3% ethnic minority residents may influence primary care demand

    Across 41,974 registered patients, Dartford Central PCN has a younger demographic: 24.7% are aged 0-17 against 23.3% in Dartford, 20.7% in NHS Kent and Medway ICB and 19.6% in England, led by Temple Hill Surgery at 28.1%. Conversely, 13.8% are aged 65+ (Dartford 15.1%, ICB 19.9%, England 17.9%). Census resident estimates show 27.3% ethnic minority residents, including 11.4% Black or Black British (Dartford 10.5%, ICB 3.1%, England 4.2%) and 10.4% Asian or Asian British (Dartford 9.9%, ICB 4.7%, England 9.6%). Projected list growth is 6.0% to 2030 (methodology unverified).

    Age profile

    0–1724.7%
    18–6461.5%
    65+13.8%

    65+: ICB 19.9%, England 17.9%

    Ethnicity

    White72.7%
    Black11.4%
    Asian10.4%
    Mixed3.3%
    Other2.2%

    Older people · falls rows are Dartford local-authority (LA) data, not PCN

    MeasureLocalSouth EastEnglandPeriod
    Falls admissions, 65+, per 100,000 (Dartford LA)2,0062,0181,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)80.2%82.2%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)56.1%57.8%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Dartford LA)1,0009819552024/25
    Falls deaths, all ages, per 100,000 (Dartford LA)14.214.014.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Deprivation is moderate at PCN level and sharply uneven between practices

    Dartford Central PCN's Core20 share is 10.9%, above Dartford (9.8%) but below NHS Kent and Medway ICB (17.1%) and England (21.0%). The weighted practice share is 11.3%, showing a 0.41 pp difference. Practice share spans 13.5 pp: Horsman's Place Surgery has the highest concentration (19.5%; 1,852 estimated patients), whereas Temple Hill Surgery holds the largest volume (2,382 estimated patients at 10.1%). Resident Core20 estimates total about 4,100. Services could balance intensive targeted outreach at high-concentration sites against routine management at high-volume practices.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Horsman's Place19.5% · 1,852 patients
    Temple Hill10.1% · 2,382 patients
    Redwood6.0% · 526 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    371

    SMI register

    0.91% recorded prevalence

    294

    Learning disability register

    0.72% recorded prevalence

    14

    Care homes, 635 beds

    In the PCN catchment

    8.6%

    Provide unpaid care

    Dartford, Census 2021

    Recorded learning disability prevalence is 0.7% (294 patients; Dartford 0.6%, NHS Kent and Medway ICB 0.6%, England 0.6%), representing 38.4% of the borough register, alongside 371 patients on the severe mental illness register (0.9%; Dartford 0.8%, England 1.0%). Catchment care homes total 14 sites with 635 beds. The PCN accounts for 38.4% of Dartford borough's learning disability register, indicating a concentrated caseload for routine clinical review across member practices.

    Severe mental illness: physical health checks

    SMI recorded prevalence is 0.9% (England 1.0%). Physical health checks trail England across individual elements: 80.7% received a blood pressure check (England 83.4%) and 78.5% had BMI recorded (England 82.1%), leaving physical risk monitoring incomplete for this cohort.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    7,170

    Hypertension register

    +20.19%

    Register growth, 3 yrs

    Dartford +7.12% · England +5.60%

    −5.85pp

    BP control, under 80

    ≤140/90 · −1.50pp aged 80+

    +4,224

    More patients by 2030

    Forecast 11,394 (25.35%)

    Hypertension case-finding and control

    Hypertension prevalence reached 17.6% (7,170 patients), rising +20.2% over three years (Dartford +7.1%, England +5.6%). However, monitoring and control trail benchmarks: recent blood pressure checks reached 82.3% (England 90.0%), and patients treated to target fell 8.1% to 60.3% (England 70.3%). Among patients aged under 80, control to <= 140/90 mmHg fell 9.4% to 56.5% (England 67.8%), with practice rates at 43.9% at Horsman's Place Surgery and 59.3% at Temple Hill Surgery. This could reflect routine review capacity lagging rapid case-finding; a recall audit would test it. Blood pressure control trails England and ICB comparators, meaning review capacity should be prioritised for systematic recall of uncontrolled patients.

    Lipids and statins

    Patients with QRISK ≥ 20% on lipid-lowering therapy reached 63.7%, rising +18.8% over three years (England +6.2% to 63.6%). Additionally, CKD lipid-lowering therapy reached 77.3% (England 70.3%, Dartford 74.3%). Lipid management is above or in line with national benchmarks, showing an opportunity to sustain proactive treatment across high-risk cohorts.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202660,911£1.90£1.90£1.86£115,731
    Cardiovascular (all), 202573,226£3.84£3.57£3.33£281,188

    For lipid-modifying drugs in 2026, the PCN prescribed 60,911 items totalling £115,731 at £1.90 per item. This was £2,436 more than at England's unit cost of £1.86, and equal to NHS Kent and Medway ICB's £1.90. Unit costs sit slightly above England while matching the ICB, indicating that the PCN could prioritise volume reviews over unit-cost switching.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −2.36%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −5.50%

    Asthma prevalence, PCN 3-yr % change

    COPD prevalence is 1.3% (England 1.9%, Dartford 1.6%), having fallen 11.1% over three years (England +2.6%), while 12-month COPD reviews fell 17.0% (England +2.8%) to 68.8% (England 76.4%). Asthma prevalence is 4.8% (England 6.6%); reviews stand at 67.4% (England 65.7%), with an estimated 589 patients on the 1,809 register lacking a 12-month review. Youth asthma prescribing is 893 items per 1,000 (England 1,488). This could reflect review capacity trailing case-finding; a recall audit would test it.

    Cancer register and children's immunisation

    Cancer prevalence is 3.3% (1,338 patients), below England (3.8%). All childhood immunisation cohorts sit below the 95.0% target: at 12 months, 6-in-1 coverage is 85.7% (England 91.0%). At age five, 4-in-1 booster coverage is 79.7% (15.3 pp below target; England 80.9%) and MMR dose 2 is 81.2% (England 82.8%), trailing first-dose coverage of 92.0% by 10.8 pp. This leaves significant pre-school immunisation gaps requiring systematic recall.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months85.7%

    England 91.0%

    6-in-1 complete primary course at 24 months90.8%

    England 92.2%

    MMR dose 1 at 24 months81.7%

    England 88.3%

    MMR dose 2 at age 581.2%

    England 82.8%

    4-in-1 pre-school booster at age 579.7%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.6%

    Kent and Medway ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~1,630

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Kent and Medway ICBEnglandNo usable stageStaged cancers
    Breast82.1%85.4%23%1,509
    Prostate54.4%53.2%37%1,435
    Lung29.4%33.8%21%1,109
    Bowel48.2%47.0%29%1,013
    Skin cancer87.5%87.8%23%562

    Across NHS Kent and Medway ICB in 2022, 55.6% of staged cancers (4,661 of 8,384) were diagnosed at stage 1 or 2, in line with England (55.3%) and at a distance of -19.4 pp to the 75.0% national ambition. Across all registered cancers, 63.6% had a known stage (England 67.0%). Sizing indicates the ICB requires 1,627 extra early-stage diagnoses annually to reach 75.0%, having changed +2.2 pp since 2013. Locally, cervical screening in women aged 25-49 is 63.9% (England 66.8%), changing -2.9% over three years (England -1.0%). Systematic screening recall could help identify early pre-cancerous lesions before symptomatic progression.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In July 2026, Dartford and Gravesham NHS Trust met the 28-day faster diagnosis standard at 78.1% (standard 75.0%; Lewisham and Greenwich NHS Trust 83.7%, England 79.3%, NHS Kent and Medway Integrated Care Board 76.8%) and the 31-day standard at 97.5% (standard 96.0%; England 92.5%). However, the Trust's 62-day referral to treatment was 63.6%, showing a distance of -21.4 pp to the 85.0% standard (Lewisham and Greenwich NHS Trust 69.0%, England 71.2%, ICB 75.9%). For all diagnostic tests, 8.4% waited 6+ weeks at the Trust (England 23.1%). Delays beyond diagnosis could reflect specialist treatment capacity rather than diagnostic backlogs.

    Pathways within standard (%)Dartford and GraveshamLewisham and GreenwichKent and Medway ICBEngland
    28-day faster diagnosis (75%)78.1483.7476.7879.32
    31-day treatment (96%)97.4895.2495.8492.50
    62-day referral to treatment (85%)63.5968.9875.9371.16
    Diagnostic waits over 6 weeks (%)Dartford and GraveshamKent HealthLewisham and GreenwichEngland
    MRI0.36—2.3021.40
    CT2.08—10.219.92
    Echocardiography3.90—6.8228.48
    Colonoscopy0.40—19.6530.83
    Gastroscopy0.00—9.4229.02
    All 15 DM01 tests8.3727.4927.5823.14
    Community services activityKent residentsKent and Medway ICB
    Care contacts210,170254,055
    Referrals59,36068,085
    Patients with a contact60,60572,060

    Community services (residents of Kent), Jun 2026 (provisional). At local authority and system level (not PCN performance), provisional experimental community services data for June 2026 recorded 210,170 care contacts and 265,905 care activities across 60,605 Kent residents, within an ICB total of 254,055 contacts and 297,595 activities. Adults aged 65+ accounted for 65.8% of Kent contacts (138,250), reflecting a high concentration of community contacts among older residents across the wider system.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Patient experience varies by 23.8 percentage points across practices alongside uneven phone access

    In 2025/26, QOF overall achievement was 90.4% at Redwood Practice, 89.3% at Temple Hill Surgery, and 82.8% at Horsman's Place Surgery (England 92.5%). Clinical achievement was 100.0% at Redwood Practice, 98.6% at Temple Hill Surgery, and 89.2% at Horsman's Place Surgery.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Horsman's Place9419.546.8%69.0%77.3%
    Redwood Practice1176.030.0%66.0%72.9%
    Temple Hill8810.129.9%72.1%53.4%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNDartfordAssetPCNDartford
    Care homes (catchment)14 (635 beds)n/aSchools (catchment)79n/a
    Children's centres57Places of worship3641
    Libraries57Homelessness support (VCS)n/a1
    Day centres (VCS)75Children and young people (VCS)11
    Carers support groups (VCS)n/a3Primary schools (LA maintained)56
    Primary academies1422

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Hypertension BP review and titration recall

    On the 7,170 register, BP treated to target is 60.3% (England 70.3%, fell 8.1%), and under-80s control is 56.5% (England 67.8%, fell 9.4%; Horsman's Place Surgery 43.9%, Temple Hill Surgery 59.3%). For discussion, run pharmacist-led recall and titration clinics for hypertensive patients above target, starting with under-80s. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 2

    Respiratory and heart failure review recall

    Asthma reviews are 67.4% (589 of 1,809 unreviewed). COPD reviews fell 17.0% to 68.8% (England 76.4%; gap +136 to +254) and heart failure fell 14.3% to 73.5% (England 78.5%; gap +47 to +170). For discussion, use a combined recall template to review unreviewed asthma, COPD and heart failure patients. Moderate effort to run.

    Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.

    Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.

    Option 3

    Pre-school booster and cervical screening recall

    Age-5 4-in-1 coverage is 79.7% (below the 95.0% target by 15.3 pp) and MMR2 is 81.2% (10.8 pp below MMR1 at 92.0%; 13.3 pp at Temple Hill Surgery). Cervical screening fell 2.9% to 63.9% (England 66.8%). For discussion, audit overdue pre-school immunisation and cervical screening lists with flexible clinics. Low cost, quick to run.

    Evidence base: uptake is the delivery measure of the national cancer screening programme; distance to the acceptable and achievable standards is the outreach target.

    Policy anchor: Shift 3: sickness to prevention; Eliminate cervical cancer by 2040.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Paediatric access and clinic review (p2)Aged 0-17Medium Term Planning Framework 2026 · Neighbourhood health frameworkPCN
    Two-track Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical check recall (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension blood pressure control review (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall outreach (p6)4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall outreach (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Telephony and triage review (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Hypertension BP review and titration recall (p12)Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP readingCore20PLUS5 CVD · CVDPREVENT 2029PCN & Practice
    Option 2 · Respiratory and heart failure review recall (p12)COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 monthsCore20PLUS5 respiratoryPCN
    Option 3 · Pre-school booster and cervical screening recall (p12)4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026ICB2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15